CLIMB BIO, INC. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets
CLIMB BIO, INC. (CLYM) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets of $54.72 million as of 2024-12-31, per its 10-K filed 2025-03-25.
Financial Statements › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) › Business Combination, Recognized Asset Acquired, Asset, Current
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets · last filed 2026-03-05
- 2024-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets $54.72M.
- 2024-09-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets $54.72M.
- 2024-06-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets $54.72M.
- 2024-06-27: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets $54.72M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets |
|---|---|
| 2024-12-31 | $54.72M 10-K · filed 2025-03-25 |
| 2024-09-30 | $54.72M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $54.72M 10-Q · filed 2024-08-14 |
| 2024-06-27 | $54.72M 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |